Novo Nordisk (NVO) Stock Jumps 7% as Oral Wegovy Lands in the UK

TLDR

• NVO stock rose 6.55% on June 22, 2026
• The UK approved an oral (pill) version of Wegovy — the first oral GLP-1 approved for weight management in the UK
• The Novo Nordisk Foundation launched the CardioMetabolic Bridge, a pan-European obesity and diabetes research initiative
• Berenberg analyst Kerry Holford raised the price target on NVO to DKK 325 from DKK 300, maintaining a Buy rating
• Risks remain, including a growing debt load and heavy reliance on GLP-1 drugs in the US

Novo Nordisk (NVO) stock climbed 6.55% on June 22 as two pieces of news landed on the same day, giving investors fresh reasons to buy into the obesity drug story.

Novo Nordisk A/S, NVO

The stock was trading against a rough year-to-date backdrop — NVO is still down about 12.90% in 2026 — so the jump stood out.

The bigger of the two catalysts was the UK approval of an oral version of Wegovy. Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) gave the green light on June 11, making it the first oral GLP-1 receptor agonist approved for weight management in the UK.

The pill is approved as an add-on to a reduced-calorie diet and exercise for adults with obesity or overweight who also have at least one weight-related condition. The decision was backed by data from the Phase 3 OASIS 4 trial.

Up until now, patients in the UK had to use injectable versions of Wegovy. A pill option could open the treatment up to people who are reluctant to self-inject, which may drive higher prescription volumes over time.

CardioMetabolic Bridge Adds to the Momentum

The second catalyst was the launch of the CardioMetabolic Bridge, a large pan-European research initiative funded by the Novo Nordisk Foundation. The program is designed to speed up the development of new treatments for obesity and type 2 diabetes.

The initiative is separate from the company itself, but it sends a clear signal to the market: there is long-term institutional backing behind innovation in Novo Nordisk’s core drug categories.

Together, the two developments reinforced the idea that Novo Nordisk is not standing still in a competitive space.

On the analyst side, Berenberg’s Kerry Holford raised the price target on NVO to DKK 325 from DKK 300 on June 17, while keeping a Buy rating in place.

The current market cap sits at $199.8 billion. Average daily trading volume runs at around 15.4 million units.

Risks Still on the Table

The bullish headlines don’t erase the concerns that have weighed on NVO in 2026.

The company carries a growing debt load. Weaker cash generation makes it more exposed if interest rates stay elevated.

There is also the concentration risk. A large portion of Novo Nordisk’s revenue comes from GLP-1 and obesity drugs, particularly in the US market. Any pricing pressure, changes in insurance coverage, or a faster-than-expected move by rivals could create earnings volatility.

The technical sentiment signal on NVO is currently rated as Sell, suggesting the chart-watchers have not yet turned positive even after today’s move.

The short interest as a percentage of outstanding stock is just 0.51%, meaning there is not a large short position that would amplify any further rally.

As of the close on June 22, NVO was up 6.55% on the session, with the oral Wegovy UK approval and the CardioMetabolic Bridge initiative cited as the primary drivers of the move.

The post Novo Nordisk (NVO) Stock Jumps 7% as Oral Wegovy Lands in the UK appeared first on CoinCentral.